Cumulative
0
0
Reply to "The Cumulative Hazard of Adalimumab De-escalation: Lessons from the 3-Year LADI Follow-Up"
Reply to "The Cumulative Hazard of Adalimumab De-escalation: Lessons from the 3-Year LADI Follow-Up"
admin
0
0
The Cumulative Hazard of Adalimumab De-escalation: Lessons from the 3-Year LADI Follow-Up